Hypothyroidism in Noninterferon Treated-HCV Infected Individuals Is Associated with Abnormalities in the Regulation of Th17 Cells
Table 1
Clinicoserological findings in hypo- and normothyroidism HCV patients.
Group A ( = 20)
Group B ( = 67)
Control ( = 40)
value
Females/males
14/6
48/19
20/20
—
Age, mean ±SD (years)
49.8 ± 9.7
49.8 ± 12.2
51.2 ± 14.9
NS
HCV genotype
1
12
45
0
—
2
7
21
0
—
4
1
—
Viral load HCV RNA (50 IU/mL)
489,731 ± 381,451
399,129 ± 319,863
Negative
NS
ALT (IU/mL)
99.75 ± 65.58
81.23 ± 55.38
25 ± 1.62
NS
AST (IU/mL)
81.37 ± 54.31
72.28 ± 54.33
32 ± 1.33
NS
Platelets (k/L)
162 ± 73.3
206.6 ± 85.1
309 ± 95
NS
Albumine (g/dL)
4 ± 0.48
3.9 ± 0.8
4.1 ± 0.4
NS
TSH (IU/mL)
Total
6.45 ± 2.21
2.58 ± 0.95
Males
5.82 ± 1.73
2.26 ± 0.76
2.6 ± 1.1
.0001
Females
6.71 ± 2.40
2.68 ± 0.99
T3 (ng/mL)
1.4 ± 0.9
1.51± 0.6
1.3 ± 0.5
NS
T4F(ng/dL)
1.18 ± 0.4
1.51 ± 0.6
0.9 ± 0.3
NS
Anti-thyroperoxidase antibody (AbTPO)
33%
7%
Negative
.001
Anti-thyroglobulin antibody (AbTg)
41%
33%
Negative
.01
Anticyclic Citrullinated Peptides antibody (CCP)
Negative
Negative
Negative
—
Glomerular Basement Membrane (GBM)
Negative
Negative
Negative
—
Cardiolipin
Negative
Negative
Negative
IL-2 (pg/mL)
643.07 ± 572.66
292.89 ± 335.91
6.8 ± 2.7
.0009
IL-10 (pg/mL)
14.83 ± 2.98
15.27 ± 1.70
4.9 ± 1.4
NS
IL-12 (pg/mL)
271.59 ± 2.98
221.13 ± 101.60
52.7 ± 8.1
NS
IL-17 (pg/mL)
25.88 ± 23.14
14.60 ± 7.83
6.75 ± 1.14
.001
TGF- (pg/mL)
618.97 ± 221.89
850.14 ± 415.64
398 ± 271
.019
Group A are the hypothyroid HCV+ patients whereas group B are the normothyroid HCV+ patients. Percentage of patients with values above the normal range. < .01 between group A and group B.
